Healthcare Mega-Trends

GLP-1 receptor agonists — Eli Lilly's Mounjaro and Zepbound, Novo Nordisk's Ozempic and Wegovy — represent the most commercially significant drug class since statins. The obesity epidemic affects 42% of US adults. Cardiovascular outcome data is increasingly compelling. FDA approvals are expanding into new indications. The addressable market, currently estimated at $100 billion annually by 2030, may prove conservative.

The supply constraint story is transitioning. Both Lilly and Novo Nordisk have invested aggressively in manufacturing expansion. Lilly's Concord, North Carolina facility represents a $9 billion commitment to domestic production scale. Novo's capital programme spans multiple continents. By late 2026, supply-driven demand rationing should ease — shifting the debate from 'can they make enough?' to 'at what price, and for whom?'

The downstream implications are underappreciated by most investors. Reduced obesity prevalence carries negative long-term revenue implications for medical device companies focused on weight-related cardiovascular interventions. Bariatric surgery volumes are already declining measurably. Hospital systems treating obesity-related comorbidities face structural headwinds. This disruption is diffuse, slow-moving, and not yet fully priced across the healthcare sector.

Biosimilar risk represents the most significant medium-term threat to GLP-1 incumbents. Semaglutide patent cliffs begin in the early 2030s. However, the manufacturing complexity of large-molecule biologics creates a meaningful lead-time advantage for incumbents. First biosimilar entrants will likely capture only modest market share due to clinical trust dynamics inherent in injectable drug markets — a dynamic well-documented in insulin and adalimumab precedents.